Thomas Catinazzo Sells 1,459 Shares of Relay Therapeutics (NASDAQ:RLAY) Stock

Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo sold 1,459 shares of Relay Therapeutics stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $18.61, for a total transaction of $27,151.99. Following the completion of the transaction, the chief financial officer directly owned 158,285 shares in the company, valued at $2,945,683.85. This represents a 0.91% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Thomas Catinazzo also recently made the following trade(s):

• On Monday, July 6th, Thomas Catinazzo sold 17,717 shares of Relay Therapeutics stock. The stock was sold at an average price of $18.69, for a total transaction of $331,130.73.
• On Monday, June 22nd, Thomas Catinazzo sold 187,163 shares of Relay Therapeutics stock. The shares were sold at an average price of $16.97, for a total transaction of $3,176,156.11.
• On Thursday, May 14th, Thomas Catinazzo sold 17,717 shares of Relay Therapeutics stock. The shares were sold at an average price of $12.86, for a total transaction of $227,840.62.

Relay Therapeutics Stock Performance

Shares of NASDAQ:RLAY opened at $18.83 on Friday. The stock has a market capitalization of $3.61 billion, a price-to-earnings ratio of -11.99 and a beta of 1.67. Relay Therapeutics, Inc. has a 1-year low of $3.03 and a 1-year high of $20.79. The company has a 50 day moving average price of $17.16 and a 200 day moving average price of $13.07.

Relay Therapeutics (NASDAQ:RLAY) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.06). The business had revenue of $3.00 million during the quarter, compared to the consensus estimate of $5.58 million. On average, sell-side analysts expect that Relay Therapeutics, Inc. will post -1.57 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on RLAY shares. Citigroup reaffirmed an “outperform” rating on shares of Relay Therapeutics in a research report on Wednesday, May 20th. Oppenheimer increased their price target on Relay Therapeutics from $14.00 to $18.00 and gave the company an “outperform” rating in a research report on Tuesday, April 28th. Guggenheim lifted their price target on Relay Therapeutics from $22.00 to $26.00 and gave the stock a “buy” rating in a research note on Tuesday, May 26th. Wall Street Zen upgraded Relay Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, June 6th. Finally, Zacks Research lowered shares of Relay Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Wednesday, July 22nd. Two investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $24.92.

Hedge Funds Weigh In On Relay Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in RLAY. Commodore Capital LP purchased a new position in Relay Therapeutics during the 2nd quarter worth approximately $46,191,000. Perceptive Advisors LLC lifted its holdings in shares of Relay Therapeutics by 412.3% in the first quarter. Perceptive Advisors LLC now owns 9,751,141 shares of the company’s stock valued at $97,024,000 after purchasing an additional 7,847,896 shares in the last quarter. Spruce Street Capital LP purchased a new stake in shares of Relay Therapeutics in the fourth quarter valued at $25,246,000. EcoR1 Capital LLC acquired a new stake in shares of Relay Therapeutics in the first quarter worth $18,952,000. Finally, TCG Crossover Management LLC acquired a new stake in shares of Relay Therapeutics in the third quarter worth $9,450,000. Institutional investors and hedge funds own 96.98% of the company’s stock.

Key Stories Impacting Relay Therapeutics

Here are the key news stories impacting Relay Therapeutics this week:

• Positive Sentiment: Potential earnings catalyst: Zacks expects Relay Therapeutics could exceed consensus expectations in its upcoming quarterly report, which may support near-term investor sentiment. This is only an earnings preview, not a reported result. Relay Therapeutics Expected to Beat Earnings Estimates
• Positive Sentiment: Breast cancer program draws renewed interest: Coverage says Relay’s breast cancer program has revitalized the investment story, potentially expanding the company’s opportunity in oncology. Relay Therapeutics Revitalized by Breast Cancer Program
• Positive Sentiment: Institutional ownership and analyst support remain strong: Several funds increased their positions during the first quarter, and recent analyst targets generally imply additional upside. MarketBeat reports a “Moderate Buy” consensus rating with an average target of $24.92.
• Neutral Sentiment: Second-quarter results are scheduled for August 6: Relay will report financial results and corporate updates after the market close. Investors will likely focus on pipeline progress, cash resources and development plans. Relay Therapeutics Second-Quarter Results Announcement
• Neutral Sentiment: Insider selling was administrative: CFO Thomas Catinazzo and insiders Donald Bergstrom and Peter Rahmer sold a combined 4,444 shares at $18.61 to cover tax withholding on vested equity awards. Each retained substantial holdings, limiting the bearish significance of the transactions. Relay Therapeutics Insider Transactions
• Negative Sentiment: Competition and clinical risk remain material: Relay is still a clinical-stage biotechnology company, and its valuation depends heavily on successful trials and eventual commercialization. Intense competition in breast cancer could limit the program’s upside.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.